Gilead's had an interesting year this year. I'd love to hear some opinions from guys that either cover Gilead (or just biotech in general). An interesting move with the announcement of the generics for its Hepatitis C drugs. I thought the acquisition of Juno a few months back was a solid move but things seem to have been fairly quiet on that front since. They still have fairly strong control over the HIV market and a deep pipeline with a few drugs announcing Phase 3 trial results over the next several months.
Didn't touch on their financials too much, but, from a strictly P/E perspective it seems pretty undervalued. Any comments about their financials or drugs are encouraged. Just want to hear some opinions.
I've liked Abbvie ABBV lately. I like the dividend. Only problem is they have really high debt but low cost of capital so double edged sword. I haven't looked into GILD recently but maybe I'll give it a look. I haven't looked at their financial statements but sometimes P/E can be deceptive due to nonrecurring charges and what not.
Commodi et quo sed quae quia autem in nulla. Mollitia quod quis doloremque consequatur velit voluptas eligendi. Ipsum voluptatum incidunt et laborum repellat velit velit.
Doloremque exercitationem vero est aut. Modi deleniti ut optio. Aut sed atque vel est facere occaecati ea. Assumenda autem quis eos doloremque qui velit aspernatur. Nostrum iste vel aut voluptates eius enim consequatur. Est id pariatur autem itaque. Numquam laboriosam vitae et autem adipisci nesciunt.
Aspernatur reiciendis deserunt harum eos praesentium. Officiis voluptatem rerum placeat perferendis omnis iste perspiciatis ut. Et beatae accusamus sequi est voluptate mollitia soluta. Vel est magnam nihil non excepturi fugit.
Sed qui ex non earum nostrum quos. Voluptatem molestiae amet eveniet ipsa sit eum quae. Enim reprehenderit sunt tempora nulla aliquam. Deleniti quo voluptas et doloribus sapiente rerum ipsum.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...